t(3;4)(p21;q34)
Adriana Zamecnikova

Kuwait Cancer Control Center, Laboratory of Cancer Genetics, Department of Hematology, Shuwaikh, 70653, Kuwait

Published in Atlas Database: August 2007

Online updated version: http://AtlasGeneticsOncology.org/Anomalies/t0304p21q34ID1433.html
DOI: 10.4267/2042/38562

This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence.
© 2008 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity

Phenotype / cell stem origin
MDS-RA and M1 AML by FAB criteria, a primitive myeloid progenitor is likely to be involved.

Etiology
No known prior exposure.

Epidemiology
Only 2 cases to date, a 69 year old female and a 31 year old male, sex ratio 1M/1F.

Clinics
Elevated WBC (68x10^9 l), 93% blasts in blood, lymphadenopathy, hepatosplenomegaly, high LDH in AML patient.

Cytology
Positive for CD 34, HLDR, CD33, CD68, MPO in AML.

Treatment
Chemotherapy followed by bone marrow transplantation in AML.

Evolution
After the first cycle of therapy, persistent bone marrow infiltration with 11% blasts.

Prognosis
Survival 6 month in MDS, 15 month+ in AML.

Cytogenetics

Identity

Clinics and pathology

Disease
Myeloid lineage, found in 1 myelodysplastic syndrome (MDS) and 1 Acute Myeloid Leukemia (AML).

Cytogenetics morphological
May be misinterpreted as t(3;5) in suboptimal preparations.

Cytogenetics molecular
FISH analysis is recommended to exclude the more frequent t(3;5).
**Probes**
WCP 3 and 4 probes, locus specific BCl6 and 5q probes.

**Additional anomalies**
t(3;4)(p21;q34) is part of a complex karyotype in MDS case associated with del(20q), sole abnormality in AML case.

**Genes involved and Proteins**

**Note:** 3p21 is a recurrent breakpoint in MDS/AML and t-MDS/t-AML suggesting, 3p21 site is likely to contain a gene (genes) involved in the pathogenesis of t(3;4)(p21;q34). Frequent deletion or allelic loss of band 3p21 is common in solid tumors, indicating the presence of tumor suppressor genes on this chromosome arm. The association among structural chromosome 3 aberrations and fragile sites on 3p may indicate the importance of previous mutagen exposure in the etiology of these diseases.

Although several cancer-related genes have been located to 3p21, no gene has yet been identified to be related with hematological malignancies. One of the candidate genes may be the AF3p21 gene, a novel fusion partner of the MLL gene described in a patient who had developed therapy-related leukemia with t(3;11)(p21;q23). AF3p21 encodes a protein localized exclusively in the cell nucleus, suggesting the possibility that AF3p21 protein plays a role in signal transduction in the nucleus.

**References**


This article should be referenced as such: Zamecnikova A. t(3;4)(p21;q34). Atlas Genet Cytogenet Oncol Haematol.2008;12(4):347-348.